News | Peripheral Artery Disease (PAD) | August 14, 2018

Lokai Medical to Distribute NuCryo Vascular PolarCath Balloon Dilatation System in U.S.

Cryoplasty system offers controlled cooling of the plaque and artery wall during peripheral artery disease treatment

Lokai Medical to Distribute NuCryo Vascular PolarCath Balloon Dilatation System in U.S.

August 14, 2018 — NuCryo Vascular announced that the company has signed a commercialization agreement with Lokai Medical, a specialty distributor of coronary/peripheral and interventional devices, to distribute the PolarCath Balloon Dilatation System in the United States.

The controlled cooling of the plaque and artery wall in balloon cryoplasty provides three potential benefits: uniform vessel dilation with less vessel trauma, reduced vessel wall recoil and induction of apoptosis, which promotes the natural cell death of the smooth muscle cells that otherwise proliferate to cause restenosis. The PolarCath Cryoplasty system was invented by James Joye, M.D., an interventional cardiologist in Mountain View, Calif. who is a pioneer in the development of medical devices to treat peripheral arterial disease (PAD).

“I am very excited for the next-generation reusable cryoplasty inflation device that NuCryo has re-engineered and brought back to market,” said Jonathan Aliota, M.D., interventional cardiologist from Houston. “As a previous cryoplasty user with Boston Scientific, I recently reincorporated it back into my peripheral treatment algorithm and have been extremely happy with the results. In addition, the cost, ease of use and time savings as compared to other balloons on the market have been well received at my facility.”

The PolarCath Peripheral Dilatation System received U.S. Food and Drug Administration (FDA) clearance to dilate stenosis in the peripheral vasculature (iliac, femoral, popliteal, infrapopliteal, renal and subclavian arteries) and for the treatment of obstructive lesions of polytetrafluoroethylene (PTFE) access grafts or arteriovenous dialysis fistulae. The PolarCath System is also indicated for post-deployed stent expansion of self-expanding peripheral vascular stents.

For more information: www.nucryovasc.com


Related Content

News | Peripheral Artery Disease (PAD)

June 6, 2025 – A large retrospective review of more than 100,000 patients found the use of glucagon-like peptide-1 ...

Home June 06, 2025
Home
News | Peripheral Artery Disease (PAD)

Feb. 3, 2025 — Today, Peripheral Artery Disease (PAD) affects 10 million Americans and is the most common cause of limb ...

Home February 04, 2025
Home
News | Peripheral Artery Disease (PAD)

Jan. 13, 2025 – R3 Vascular Inc., a medical device company dedicated to treating peripheral arterial disease (PAD) ...

Home January 13, 2025
Home
News | Peripheral Artery Disease (PAD)

A new study reports persistent disparities in outcomes for people with peripheral artery disease (PAD) and its more ...

Home January 13, 2025
Home
News | Peripheral Artery Disease (PAD)

Dec. 13, 2024 – Sensome has announced positive results from two studies of its Clotild Smart Guidewire System ...

Home December 16, 2024
Home
News | Peripheral Artery Disease (PAD)

Nov. 18, 2024 — In November, Esperion presented an analysis from the CLEAR Outcomes study focused on patients with ...

Home December 03, 2024
Home
News | Peripheral Artery Disease (PAD)

Nov. 4, 2024 — Royal Philips recently announced enrollment of the first patient in the U.S. THOR IDE clinical trial ...

Home November 08, 2024
Home
News | Peripheral Artery Disease (PAD)

Sept. 16, 2024 – Shockwave Medical, Inc., part of Johnson & Johnson MedTech, has announced the full U.S. launch of the ...

Home September 16, 2024
Home
News | Peripheral Artery Disease (PAD)

Sept. 1, 2024 — September is Peripheral Artery Disease (PAD) Awareness Month, a time to educate and empower people to ...

Home September 04, 2024
Home
News | Peripheral Artery Disease (PAD)

May 16, 2024 — Timely diagnosis and proper management of peripheral artery disease (PAD), including coordinated care ...

Home May 16, 2024
Home
Subscribe Now